Showing 2381-2390 of 5696 results for "".
- Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at ASCRShttps://modernod.com/news/orasis-pharmaceuticals-to-present-new-data-on-novel-presbyopia-candidate-at-ascrs/2480764/Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C. "We look forward to these present
- Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseaseshttps://modernod.com/news/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases/2480756/Opus Genetics announced a strategic manufacturing services agreement with National Resilience, a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline. Resilience
- AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Diseasehttps://modernod.com/news/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-of-dry-eye-disease/2480753/AXIM Biotechnologies announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for dry eye disease. "Dry eye disease, though widespread, is under-diagnosed, in part because symptoms do not always
- Novartis Receives European Commission Approval of Beovu for Diabetic Macular Edema (DME)https://modernod.com/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme/2480740/Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the
- Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Devicehttps://modernod.com/news/olympic-ophthalmics-announces-fda-clearance-and-availability-of-its-next-generation-itear100-neurostimulation-device-expanded-patent-portfolio-and-further-clinical-studies/2480737/Olympic Ophthalmics announced that the FDA has granted 510(K) clearence for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The second-generation device is a connected device o
- Nova Eye President Appointed to American Glaucoma Society (AGS) Foundation Advisory Boardhttps://modernod.com/news/nova-eye-president-appointed-to-american-glaucoma-society-ags-foundation-advisory-board/2480735/Nova Eye Medical has announced that Joe Bankovich, President of Nova Eye, has been appointed as an industry representative to the American Glaucoma Society Foundation Advisory Board. Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- New Multi-Language Options Now Available on Reichert.comhttps://modernod.com/news/new-multi-language-options-now-available-on-reichertcom/2480719/Reichert Technologies, a business unit of Ametek, has announced that Reichert.com is now available in five new language options: Chinese, French, German, Italian, and Spanish. Putting customers first will always be Reichert’s main focus. This new capability will help make the information on
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,